Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SKYE - Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

SKYE - Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

Skye Bioscience Inc Com

--News Direct--

Skye Bioscience CEO Punit Dhillon joins Proactive's Natalie Stoberman to discuss the positive safety review for its Phase 2 clinical trial for its SBI-100 Ophthalmic Emulsion.

Dhillon said the trial's safety review committee has recommended that the trial continue without modification. Now, the company is preparing for Phase 3 recruitment for the third cohort of eight participants with dosing planned for March.

Contact Details

Proactive Investors US

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/skye-bioscience-moving-ahead-with-sbi-100-clinical-trial-after-positive-safety-review-305519961

Stock Information
Company Name: Skye Bioscience Inc Com
Stock Symbol: SKYE
Market: NASDAQ
Website: skyebioscience.com
Menu
SKYE SKYE Quote SKYE Short SKYE News SKYE Articles SKYE Message Board
Get SKYE Alerts

News, Short Squeeze, Breakout and More Instantly...